BICO Group AB (OTCPK:BCCOY)

$ 0.8819 0 (0%) Market Cap: 248.96 Mil Enterprise Value: 365.35 Mil PE Ratio: 0 PB Ratio: 0.84 GF Score: 68/100

Q3 2024 BICO Group AB Earnings Call Transcript
6 days ago

$0.8819

Earnings
Q2 2024 BICO Group AB Earnings Call Transcript
Aug 20, 2024

$1.05

Earnings
BICO Group AB Corporate Call Transcript
Aug 22, 2023
Q2 2023 BICO Group AB Earnings Call Transcript
Aug 22, 2023

$0.8949

Earnings
Q1 2023 BICO Group AB Earnings Call Transcript
May 04, 2023

$1.25

Earnings
Q4 2022 BICO Group AB Earnings Call Transcript
Feb 22, 2023

$2.25

Earnings
BICO Group AB Corporate Analyst Meeting Transcript
Nov 10, 2022
Q3 2022 BICO Group AB Earnings Call Transcript
Nov 09, 2022

$0.939

Earnings
Half Year 2022 BICO Group AB Earnings Call Transcript
Aug 24, 2022

$0.85 (-15.00%)

Earnings
Half Year 2022 BICO Group AB Earnings Call Transcript
Aug 24, 2022

$0.85 (-15.00%)

Earnings
Preliminary Q2 2022 BICO Group AB Earnings Call Transcript
Jul 18, 2022

$0.75 (-65.91%)

Earnings
Q1 2022 BICO Group AB Earnings Call - Afternoon Session Transcript
May 18, 2022

$2.6

Earnings
Q1 2022 BICO Group AB Earnings Call - Morning Session Transcript
May 18, 2022

$2.6

Earnings
Q4 2021 BICO Group AB Earnings Call Transcript
Feb 23, 2022

$4 (-39.94%)

Earnings

Preliminary Q2 2022 BICO Group AB Earnings Call Transcript

Jul 18, 2022 / 08:00AM GMT

Release Date Price: $0.75 (-65.91%)

Transcript

Erik Gatenholm;publ;Co;Founder

BICO Group AB;CEO, President & Director

()-- -

And thank you so much, everyone, for taking the time today. We really appreciate it. I'm here. I'm Erik Gatenholm, Co-Founder, CEO of BICO, I'm here with Mikael Engblom, Interim CFO. And the purpose of this call is to present the preliminary results and provide a trading update for the group.

I would like to start by, of course, thanking the entire team for the continued strong efforts in Q2, and that's truly been a great pleasure working with everyone serving our global customers around the world. We're on an exciting journey together to create the future of life-saving treatments with our customers and look forward to continuing to serve their laboratory needs. Next slide, please.

With that being said, we now see market slowdowns in emerging biopharma and biotech as a consequence of the recent macroeconomical challenges. While demand for our products remain strong and we can point to healthy underlying demand worldwide in the second quarter, which

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.